Brought to you by 
Roche signs GPCR discovery deal with Confo Therapeutics
20 Dec 2017
Executive Summary
Confo Therapeutics NV licensed Roche exclusive rights to discover, develop, manufacture, and sell small-molecule G-protein coupled receptor (GPCR) agonists for neurological and developmental disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche signs GPCR discovery deal with Confo Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice